Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB known ✓ | P09619 | 8/20 | 0.70 |
| ▸ | KDR known ✓ | P35968 | 4/20 | 0.68 |
| ▸ | CSF1R | P07333 | 15/20 | 0.70 |
| ▸ | PDGFRA | P16234 | 11/20 | 0.70 |
| ▸ | MET | P08581 | 6/20 | 0.70 |
| ▸ | FLT3 | P36888 | 5/20 | 0.70 |
| ▸ | AXL | P30530 | 3/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2409842 | 0.97 | CSF1R (0.74) | CSF1RPDGFRAPDGFRBMETFLT3 | |
| SCHEMBL2411671 | 0.90 | CSF1R (0.80) | CSF1RPDGFRAPDGFRBMETFLT3 | |
| SCHEMBL2412058 | 0.84 | CSF1R (0.78) | CSF1RPDGFRAPDGFRBMETFLT3 | |
| SCHEMBL3494677 | 0.83 | CSF1R (0.59) | CSF1RPDGFRAPDGFRBMETFLT3 | |
| SCHEMBL2414920 | 0.83 | MET (1.00) | CSF1RPDGFRAPDGFRBMETFLT3 | |
| SCHEMBL2445694 | 0.81 | CSF1R (0.82) | CSF1RPDGFRAPDGFRBMETFLT3 | |
| SCHEMBL2417598 | 0.81 | CSF1R (1.00) | CSF1RPDGFRAPDGFRBMETFLT3 | |
| SCHEMBL2411009 | 0.80 | CSF1R (1.00) | CSF1RPDGFRAPDGFRBMETFLT3 | |
| SCHEMBL2415429 | 0.80 | MET (0.56) | CSF1RPDGFRAPDGFRBMETFLT3 | |
| SCHEMBL3492389 | 0.79 | CSF1R (0.65) | CSF1RPDGFRAPDGFRBMETFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2365752-B1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS LLC (US) | 2014-09-24 | — | — | EP | disclosed |
| US-8486951-B2 | Cyclopropane amides and analogs exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-07-16 | — | — | US | disclosed |
| US-20130079362-A1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2013-03-28 | — | — | US | disclosed |
| US-8278331-B2 | N-acyl ureas exhibiting anti-cancer and anti-proliferative activities | DECIPHERA PHARMACEUTICALS, LLC (US) | 2012-10-02 | — | — | US | disclosed |
| EP-2365752-A1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | Deciphera Pharmaceuticals, Llc (US) | 2011-09-21 | — | — | EP | disclosed |
| US-20100120806-A1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC | 2010-05-13 | — | — | US | disclosed |
| WO-2010051373-A1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | DECIPHERA PHARMACEUTICALS, LLC (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130079362-A1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | KIT, PDGFRA, PDGFRB | PDGFRB 3/4885KDR 88/4885CSF1R 14/4885 |
| US-20100120806-A1 | CYCLOPROPANE AMIDES AND ANALOGS EXHIBITING ANTI-CANCER AND ANTI-PROLIFERATIVE ACTIVITIES | KIT, PDGFRA, PDGFRB | PDGFRB 3/4885KDR 89/4885CSF1R 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.